Loading clinical trials...

RECRUITINGNA

Reducing Cognitive Impairment by Management of Heart Failure as a Modifiable Risk Factor

Reducing Cognitive Impairment by Management of Heart Failure as a Modifiable Risk Factor: the Cog-HF Trial

NCT06088212•Baker Heart and Diabetes Institute

Summary

This study will test the feasibility and effectiveness of an innovative model of care for cognitively impaired patients with heart failure. This program aims to improve cognition, reduce dementia risk and cardiovascular events, and will be supported by innovative digital technology for wide scale rollout and implementation. Findings from this research will transform the way healthcare is delivered to cognitively impaired patients with heart disease who have a very high risk of developing dementia.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Hospitalised with HF as primary or secondary diagnosis.
•2. At least mild cognitive impairment (CI) based on Montreal Cognitive Assessment (MoCA) on hospital discharge.

Exclusion Criteria

•1. Unable to provide written consent; requiring palliative care; or participating in another RCT
•2. Recovery of cognitive function shortly after hospital discharge: to ensure that we only include patients with "true" CI, any patients with a repeated MoCA\>25 at 2 weeks post-discharge will be excluded.
•3. Terminal illness (eg. cancer) that may influence 12-month prognosis.

Locations (1)

Menzies Institute for Medical Research

Hobart, Tasmania, Australia

Key Dates

Start Date

July 1, 2024

Primary Completion Date

October 1, 2025

Completion Date

July 1, 2026

Last Updated

August 12, 2024

Enrollment

168

ESTIMATED participants

Conditions

Heart FailureCognitive ImpairmentDementiaLeft Ventricular DysfunctionCognitive ChangeCognitive Decline

Interventions

Disease management program

OTHER

Contacts

Quan Huynh

CONTACT

610385321833 quan.huynh@baker.edu.au

ML Score Prediction of Cardiotoxicity in Cancer Patients Receiving Anthracycline Chemotherapy or HER2-Targeted Therapies

NCT07191730

CardiotoxicityHeart Failure+2 more

View study

RECRUITINGNA

ReDS-guided Decongestion Strategy in Patients Hospitalized for Heart Failure

NCT07484009

Acute Heart Failure (AHF)Heart Failure (for Example, Fluid Overload)+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 12, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Reducing Cognitive Impairment by Management of Heart Failure as a Modifiable Risk Factor

Inclusion Criteria

Exclusion Criteria

ML Score Prediction of Cardiotoxicity in Cancer Patients Receiving Anthracycline Chemotherapy or HER2-Targeted Therapies

ReDS-guided Decongestion Strategy in Patients Hospitalized for Heart Failure

Sense4Safety Intervention

Choline to Improve Malnutrition and Enhance Cognition

[18F]F-DOPA Imaging in Patients With Autonomic Failure

Hemodynamic Monitoring to Prevent Adverse Events foLlowing cardiOgenic Shock Trial